Kiniksa Pharmaceuticals, Ltd. (KNSA) Misses Q4 EPS by 18c

Kiniksa Pharmaceuticals, Ltd. (NASDAQ: KNSA) reported Q4 EPS of $0.17, $0.18 worse than the analyst estimate of $0.35. Revenue for the quarter came in at $202.13 million versus the consensus estimate of $199.61 million.

For earnings history and earnings-related data on Kiniksa Pharmaceuticals, Ltd. (KNSA) click here.

You May Also Be Interested In

• Science Applications Int'l (SAIC) Tops Q2 EPS by 70c
• Adobe extends Saudi partnership with $4 billion AI access plan
• Westrock Coffee Co. (WEST) Reiterated at Buy by Benchmark Amid Ongoing Inflection